[en] We conducted a multicenter cohort study to determine the effect of drug therapies on survival in mechanically ventilated patients with coronavirus disease 2019. All consecutive adult patients admitted to ICU for coronavirus disease 2019 from March 1, 2020, to April 25, 2020, and under invasive mechanical ventilation for more than 24 hours were included. Out of 2,003 patients hospitalized for coronavirus disease 2019, 361 were admitted to ICU, 257 were ventilated for more than 24 hours, and 247 were included in the study. Simple and multiple time-dependent Cox regression models were used to assess the effects of factors on survival. Methylprednisolone administration during the first week of mechanical ventilation was associated with a decrease in mortality rate from 48% to 34% (p = 0.01). Mortality was significantly associated with older age, higher creatinine, lower lymphocyte count, and mean arterial pressure lower than 70 mm Hg on the day of admission.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Lambermont, Bernard ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Ernst, Marie ; Centre Hospitalier Universitaire de Liège - CHU > Département de gestion des systèmes d'informations (GSI) > Secteur d'appui à la recherche clinique et biostatistique
Fadel R, Morrison AR, Vahia A,. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020 May 19. [online ahead of print]
Horby P, Lim WS, Emberson JR, RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med. 2020 Jul 17. [online ahead of print]
Sterne JAC, Murthy S, Diaz JV, WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020; 324: 1330-1341
Auld SC, Caridi-Scheible M, Blum JM,. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020; 48: e799-e804
Cummings MJ, Baldwin MR, Abrams D,. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. Lancet. 2020; 395: 1763-1770
Argenziano MG, Bruce SL, Slater CL,. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. BMJ. 2020; 369: m1996
Grasselli G, Zangrillo A, Zanella A, COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323: 1574-1581
Yang X, Yu Y, Xu J,. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475-481
Cavalcanti AB, Zampieri FG, Rosa RG,. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 Jul 23. [online ahead of print]
Villar J, Ferrando C, Martínez D, Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8: 267-276